Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008:287–304. doi: 10.1007/978-0-387-68113-9_15

Severe Sepsis and Septic Shock

Steven M Opal 14
Editors: Jeffrey A Norton1,2, Philip S Barie3,4, R Randal Bollinger5, Alfred E Chang6, Stephen F Lowry7,8, Sean J Mulvihill9,10, Harvey I Pass11, Robert W Thompson12,13
PMCID: PMC7121326

Abstract

This chapter reviews the remarkable recent advances in the understanding of the molecular basis that underlies the pathophysiology of sepsis. This knowledge has improved diagnostic techniques and introduced new therapeutic agents into the standard management of patients with severe sepsis/septic shock. The current treatment regimens for sepsis are discussed, and the evidence to support each major treatment strategy is outlined in detail. Research priorities to further the optimal management of septic shock in the future are highlighted.

Keywords: Nitric Oxide, Septic Shock, Severe Sepsis, Acute Lung Injury, Migration Inhibitory Factor

References

  • 1.Poeze M., Ramsay G., Gerlach H., et al. International sepsis survey: A study of doctor’s knowledge and perception about sepsis. Crit Care. 2004;8:409–413. doi: 10.1186/cc2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Levy M., Ramsey G., Fink M., et al. The 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–1256. doi: 10.1097/01.CCM.0000050454.01978.3B. [DOI] [PubMed] [Google Scholar]
  • 3.Dellinger R.P., Carlet J.M., Masur H., et al. Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–871. doi: 10.1097/01.ccm.0000117317.18092.e4. [DOI] [PubMed] [Google Scholar]
  • 4.Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310. doi: 10.1097/00003246-200107000-00002. [DOI] [PubMed] [Google Scholar]
  • 5.Martin G.S., Mannino D.M., Eaton S., et al. Epidemiology of sepsis in the United States from 1979–2000. N Engl J Med. 2003;348:1546–1554. doi: 10.1056/NEJMoa022139. [DOI] [PubMed] [Google Scholar]
  • 6.Alberti C., Brun-Buisson C., Burchardi H., et al. Epidemiology of sepsis and infection in ICU patients from international multi-center cohort study. Intensive Care Med. 2002;28:108–121. doi: 10.1007/s00134-001-1143-z. [DOI] [PubMed] [Google Scholar]
  • 7.Valles J., Leon C., Alvarez-Lerma F. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin Infect Dis. 1997;24:387–395. doi: 10.1093/clinids/24.3.387. [DOI] [PubMed] [Google Scholar]
  • 8.Friedman G., Silva E., Vincent J.-L. Has the mortality of septic shock changed with time? Crit Care Med. 1998;26:2078–2086. doi: 10.1097/00003246-199812000-00045. [DOI] [PubMed] [Google Scholar]
  • 9.Sands K.E., Bates D.W., Lanken P.N., et al. Epidemiology of sepsis syndrome in eight academic medical centers. JAMA. 1997;278:234–240. [PubMed] [Google Scholar]
  • 10.Brun-Buisson C., Meshaka P., Pinton P., et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004;30:580–588. doi: 10.1007/s00134-003-2121-4. [DOI] [PubMed] [Google Scholar]
  • 11.Opal S.M., Esmon C. Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23–38. doi: 10.1186/cc1854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol. 2001;248:929–934. doi: 10.1007/s004150170043. [DOI] [PubMed] [Google Scholar]
  • 13.Brun-Buisson C., Roudot-Thoraval F., Girou E., et al. The costs of septic syndromes in the intensive care unit and the influence of hospital-acquired sepsis. Intensive Care Med. 2003;29:1464–1471. doi: 10.1007/s00134-003-1877-x. [DOI] [PubMed] [Google Scholar]
  • 14.Kreger B.E., Craven D.E., Carling P.C., McCabe W.R. Gram-negative bacteremia. IE. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med. 1980;68:332–343. doi: 10.1016/0002-9343(80)90101-1. [DOI] [PubMed] [Google Scholar]
  • 15.Pittet D., Thiívent B., Wenzel R.P., et al. Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med. 1993;19:265–272. doi: 10.1007/BF01690546. [DOI] [PubMed] [Google Scholar]
  • 16.Opal S.M., Maki D., Larosa S., et al. Systemic host response to sepsis based upon the infectious microorganism and effects of drotrecogin alfa activated. Clin Infect Dis. 2003;37:50–58. doi: 10.1086/375593. [DOI] [PubMed] [Google Scholar]
  • 17.Cohen J., Brun-Buisson C., Torres A., et al. Diagnosis of infection in sepsis: an evidence-based review. Crit Care Med. 2004;32:S466–S494. doi: 10.1097/01.ccm.0000145917.89975.f5. [DOI] [PubMed] [Google Scholar]
  • 18.Ely E.W., Wheeler A.P., Thompson B.T., et al. Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome. Ann Intern Med. 2002;136:25–29. [PubMed] [Google Scholar]
  • 19.Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751. doi: 10.1086/339215. [DOI] [PubMed] [Google Scholar]
  • 20.Styrt B. Infection associated with asplenia: risks, mechanisms and prevention. Am J Med. 1990;88:33N–42N. [PubMed] [Google Scholar]
  • 21.Sorensen T.I.A., Nielsen G.G., Andersen P.K., Teasdale T.W. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med. 1988;318:727–732. doi: 10.1056/NEJM198803243181202. [DOI] [PubMed] [Google Scholar]
  • 22.Newport M.J., Huxley C.M., Huston S., et al. A mutation in the interferon-y receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996;335:1941–1949. doi: 10.1056/NEJM199612263352602. [DOI] [PubMed] [Google Scholar]
  • 23.Beutler B. Science review: key inflammatory and stress pathways in critical illness. Crit Care. 2003;7:39–46. doi: 10.1186/cc1828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lorenz E., Mira J.-P., Frees K.G., Schwartz D.A. Relevance of mutations in the TLR4-receptor in patients with gram-negative septic shock. Arch Intern Med. 2002;162:1028–1031. doi: 10.1001/archinte.162.9.1028. [DOI] [PubMed] [Google Scholar]
  • 25.Gibot S., Cariou A., Drouet L., Rossignol M., Ripoll L. Association between a genomic polymorphism with the CD 14 locus and septic shock susceptibility and mortality rate. Crit Care Med. 2002;30:969–973. doi: 10.1097/00003246-200205000-00003. [DOI] [PubMed] [Google Scholar]
  • 26.Agnese D.M., Calvano J.E., Hahm S.J., et al. Human toll-like receptor 4 mutations but not CD 14 polymorphisms are associated with increased risk of gram-negative infections. J Infect Dis. 2002;185:1522–1525. doi: 10.1086/344893. [DOI] [PubMed] [Google Scholar]
  • 27.Mira J.P., Cariou A., Grail F., et al. Association of TNF2, a TNFα promoter polymorphism, with septic shock susceptibility and mortality. JAMA. 1999;282:561–568. doi: 10.1001/jama.282.6.561. [DOI] [PubMed] [Google Scholar]
  • 28.Read R.C., Camp N.J., Di Giovine F.S., et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis. 2000;182:1557–1560. doi: 10.1086/315889. [DOI] [PubMed] [Google Scholar]
  • 29.Nadel S., Newport M.J., Booy R., et al. Variation in the tumor necrosis factor-α gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996;174:878–880. doi: 10.1093/infdis/174.4.878. [DOI] [PubMed] [Google Scholar]
  • 30.Smirnova I., Mann N., Dols A., et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A. 2003;100:6075–6080. doi: 10.1073/pnas.1031605100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.O’Keefe G., Hybki D.L., Munford R.S. The G→ a single nucleotide polymorphism at the −308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis. J Trauma. 2002;52:817–826. doi: 10.1097/00005373-200205000-00001. [DOI] [PubMed] [Google Scholar]
  • 32.Stuber F., Petersen M., Bokelmann F., et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome patients with severe sepsis. Crit Care Med. 1996;24:381–384. doi: 10.1097/00003246-199603000-00004. [DOI] [PubMed] [Google Scholar]
  • 33.Schlüter B., Raufhake C., Erren M., et al. Effect of the interleukin-6 promoter polymorphism (−174G/C) on the incidence and outcome of sepsis. Crit Care Med. 1002;30:32–37. doi: 10.1097/00003246-200201000-00005. [DOI] [PubMed] [Google Scholar]
  • 34.Bone R.C. Gram-positive organisms in sepsis. Arch Intern Med. 1994;154:26–31. [PubMed] [Google Scholar]
  • 35.Danner R.L., Elin R.J., Hosseini J.M., et al. Endotoxemia in human septic shock. Chest. 1991;99:169–175. doi: 10.1378/chest.99.1.169. [DOI] [PubMed] [Google Scholar]
  • 36.Rietschel E.T., Kirikae T., Schade F.U., et al. Bacterial endotoxin: molecular mechanisms of structure to activity and function. FASEB J. 1994;218:217–225. doi: 10.1096/fasebj.8.2.8119492. [DOI] [PubMed] [Google Scholar]
  • 37.Pridmore A.C., Wyllie D.H., Abdillahi F., et al. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR)2 but not via TLR4/MD2. J Infect Dis. 2001;183:89–96. doi: 10.1086/317647. [DOI] [PubMed] [Google Scholar]
  • 38.Medzhitov R., Janeway C. Innate immunity. N Engl J Med. 2000;343:338–344. doi: 10.1056/NEJM200008033430506. [DOI] [PubMed] [Google Scholar]
  • 39.Fenton M.J., Golenbock D.T. LPS-binding proteins and receptors. J Leukoc Biol. 1998;64:25–32. doi: 10.1002/jlb.64.1.25. [DOI] [PubMed] [Google Scholar]
  • 40.Pugin J., Heumann I.D., Tomasz A., et al. CD 14 is a pattern recognition receptor. Immunity. 1994;1:509–516. doi: 10.1016/1074-7613(94)90093-0. [DOI] [PubMed] [Google Scholar]
  • 41.Lin Y., Leach W.J., Ammons W.S. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrobial Agents Chemother. 1996;40:65–69. doi: 10.1128/aac.40.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Levin M., Qunit P.A., Goldstein B., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet. 200;356:961–967. doi: 10.1016/s0140-6736(00)02712-4. [DOI] [PubMed] [Google Scholar]
  • 43.Poltorak A., He X., Smirnova I., et al. Defective signaling in C3H/ HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–2088. doi: 10.1126/science.282.5396.2085. [DOI] [PubMed] [Google Scholar]
  • 44.Takeuchi O., Hoshino K., Kawai T., et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 1999;11:443. doi: 10.1016/s1074-7613(00)80119-3. [DOI] [PubMed] [Google Scholar]
  • 45.Brightbill H.D., Libraty D.H., Krutzik S.R., et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999;285:732–735. doi: 10.1126/science.285.5428.732. [DOI] [PubMed] [Google Scholar]
  • 46.Cristofaro P., Opal S. The human toll-like receptors as a therapeutic target. Expert Opin Therapeutic Targets. 2003;7:603–612. doi: 10.1517/14728222.7.5.603. [DOI] [PubMed] [Google Scholar]
  • 47.Heil F., Hemmi H., Hochrein H., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526–1529. doi: 10.1126/science.1093620. [DOI] [PubMed] [Google Scholar]
  • 48.Zhang D., Zhang G., Hayden M.S., et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004;303:1522–1526. doi: 10.1126/science.1094351. [DOI] [PubMed] [Google Scholar]
  • 49.Wolbink G.J., Bossink A.W., Groeneveld A.B., et al. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis. 1998;177:81–87. doi: 10.1086/513803. [DOI] [PubMed] [Google Scholar]
  • 50.Roy S., Knox K., Griffiths D., et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet. 2002;359:1569–1573. doi: 10.1016/S0140-6736(02)08516-1. [DOI] [PubMed] [Google Scholar]
  • 51.Landmann R., Müller B., Zimmerli W. CD 14, new aspects of ligand and signal diversity. Microb Infect. 2000;2:295–304. doi: 10.1016/s1286-4579(00)00298-7. [DOI] [PubMed] [Google Scholar]
  • 52.Nau G.J., Richmond J.F., Schlesinger A., et al. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A. 2002;99:1503–1508. doi: 10.1073/pnas.022649799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Boldrick J.C., Alizadeh A.A., Diehn M., et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A. 2002;99:972–977. doi: 10.1073/pnas.231625398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Means T.K., Golenbock D.T., Fenton M.J. The biology of toll-like receptors. Cytokine Growth Factor Rev. 2000;11:219–232. doi: 10.1016/s1359-6101(00)00006-x. [DOI] [PubMed] [Google Scholar]
  • 55.Hemmi H., Osamu T., Kawai T., et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–744. doi: 10.1038/35047123. [DOI] [PubMed] [Google Scholar]
  • 56.Alexopoulou L., Holt A.C., Medzhitov R., et al. Recognition of double stranded RNA and activation of NFKB by Toll-like receptor 3. Nature. 2001;413:732–738. doi: 10.1038/35099560. [DOI] [PubMed] [Google Scholar]
  • 57.Hayayashi F., Smith K.D., Ozinski A., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;420:1099–1103. doi: 10.1038/35074106. [DOI] [PubMed] [Google Scholar]
  • 58.Choi Y., Lafferty J.A., Clements J.R.L. Selective expansion of T cells expressing Vb2 in toxic shock syndrome. J Exp Med. 1990;172:981. doi: 10.1084/jem.172.3.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Hotchkiss R.S., Karl I.E. The pathology and treatment of sepsis. N Engl J Med. 2003;348:138–150. doi: 10.1056/NEJMra021333. [DOI] [PubMed] [Google Scholar]
  • 60.Florquine S., Goldman M. Immunoregulatory mechanisms of T-cell-dependent shock induced by bacterial superantigen in mice. Infect Immun. 1996;64:3443. doi: 10.1128/iai.64.9.3443-3445.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Kusunoki T, Hailman E, Juan TS-C, et al. Molecules from Staphylococcus aureus that bind CD 14 and stimulate innate immune responses. J Exp Med 995,182:1673. [DOI] [PMC free article] [PubMed]
  • 62.Opal S.M., Huber C.E. Sepsis. Sci Am Med. 2001;30:1–17. [Google Scholar]
  • 63.Opal S.M., Scannon P.J., Vincent J.L., et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584–1589. doi: 10.1086/315093. [DOI] [PubMed] [Google Scholar]
  • 64.Tracey K.J., Beutler B., Lowry S.F., et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1998;234:470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  • 65.Bauer K.A., ten Cate H., Barzegar S., et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 1989;74:165. [PubMed] [Google Scholar]
  • 66.Fisher C.J., Slotman G.J., Opal S.M., et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22:12–21. doi: 10.1097/00003246-199401000-00008. [DOI] [PubMed] [Google Scholar]
  • 67.Dinarello C.A., Gelfand J.A., Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269:1825–1832. [PubMed] [Google Scholar]
  • 68.Luster A.D. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–442. doi: 10.1056/NEJM199802123380706. [DOI] [PubMed] [Google Scholar]
  • 69.Falk L.A., McNally R., Perera P.Y., et al. LPS-inducible responses in severe combined immunodeficiency (SCID) mice. J Endotoxin Res. 1995;2:273. [Google Scholar]
  • 70.Szabo S.J., Dinghe A.S., Gubler U., et al. Regulation of the interleukin (IL)-12Rb2 subunit expression in developing T helper 1 (Thl) and Th2 cells. J Exp Med. 1997;185:817. doi: 10.1084/jem.185.5.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Schneider C., von Aulock S., Siegfried Z., et al. Perioperative recombinant human granulocyte colony-stimulating factor (filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg. 2004;239:75–81. doi: 10.1097/01.sla.0000103062.21049.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Hotchkiss R.S., Swanson P.E., Freeman B.D., et al. Apototic cell death in patients with sepsis, shock and multiple organ dysfunction. Crit Care Med. 1999;27:1230–1251. doi: 10.1097/00003246-199907000-00002. [DOI] [PubMed] [Google Scholar]
  • 73.Kell M., Ungethüm U., Steckholzer U., et al. Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood. 1997;90:3356–3363. [PubMed] [Google Scholar]
  • 74.van Deventer S.J.H., Buller H.R., ten Cate J.W., et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood. 1990;76:2520–2526. [PubMed] [Google Scholar]
  • 75.Greenberger M.J., Strieter R.M., Kunkel S.L., et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol. 1995;155:722–729. [PubMed] [Google Scholar]
  • 76.MacMicking J., Xie Q.M., Nathan C. Nitric oxide and macrophage function. Annu Rev Microbiol. 1997;15:323–350. doi: 10.1146/annurev.immunol.15.1.323. [DOI] [PubMed] [Google Scholar]
  • 77.Shenep J.L., Toumanen E. Prospective: targeting nitric oxide in the adjuvant therapy of sepsis in meningitis. J Infect Dis. 1998;177:766–771. doi: 10.1086/514251. [DOI] [PubMed] [Google Scholar]
  • 78.Liaudet L. Poly (adenosine 5′phosphate) ribose polymerase activation as a cause of metabolic dysfunction in critical illness. Curr Opin Clin Nutr Metab Care. 2002;5:175–184. doi: 10.1097/00075197-200203000-00010. [DOI] [PubMed] [Google Scholar]
  • 79.Vervloet M.G., Thijs L.G., Hack C.E. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998;24:33–44. doi: 10.1055/s-2007-995821. [DOI] [PubMed] [Google Scholar]
  • 80.McGilvray I.D., Rotstein O.D. Role of the coagulation system in the local and systemic inflammatory response. World J Surg. 1998;22:179–86. doi: 10.1007/s002689900367. [DOI] [PubMed] [Google Scholar]
  • 81.Aird W. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765–3777. doi: 10.1182/blood-2002-06-1887. [DOI] [PubMed] [Google Scholar]
  • 82.Lorente J.A., Garcia-Frade L.J., Landin L., et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 1993;103:1536–1542. doi: 10.1378/chest.103.5.1536. [DOI] [PubMed] [Google Scholar]
  • 83.Coughlin S.R. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med. 1994;4:77–83. doi: 10.1016/1050-1738(94)90013-2. [DOI] [PubMed] [Google Scholar]
  • 84.Levi M., ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–592. doi: 10.1056/NEJM199908193410807. [DOI] [PubMed] [Google Scholar]
  • 85.Abraham E., Reinhart K., Opal S.M., et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–251. doi: 10.1001/jama.290.2.238. [DOI] [PubMed] [Google Scholar]
  • 86.Bernard G.R., Vincent J.L., Laterre P.F., et al. Safety and efficacy of activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001. [DOI] [PubMed] [Google Scholar]
  • 87.Warren B.L., Eid A., Singer P., et al. High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA. 2001;286:1869–1878. doi: 10.1001/jama.286.15.1869. [DOI] [PubMed] [Google Scholar]
  • 88.Joyce D.E., Gelbert L., Ciaccia A., et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199–11203. doi: 10.1074/jbc.C100017200. [DOI] [PubMed] [Google Scholar]
  • 89.Corrigan J.J., Jr. Heparin therapy in bacterial septicemia. J Pediatr. 1977;91:695–700. doi: 10.1016/s0022-3476(77)81017-2. [DOI] [PubMed] [Google Scholar]
  • 90.Hoffmann J.N., Vollmar B., Inthorn D., et al. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/ endothelial cell interaction and microvascular perfusion failure. Shock. 2000;14:528–534. doi: 10.1097/00024382-200014050-00006. [DOI] [PubMed] [Google Scholar]
  • 91.Wheeler A.P., Bernard G.R. Treating patients with severe sepsis. N Engl J Med. 1999;340:207–214. doi: 10.1056/NEJM199901213400307. [DOI] [PubMed] [Google Scholar]
  • 92.Esmon C.T. Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med. 2004;32:S219–S22. doi: 10.1097/01.ccm.0000127036.27343.48. [DOI] [PubMed] [Google Scholar]
  • 93.Roger T., Froidevaux C., Martin C., et al. Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4) J Endotoxin Res. 2003;9:119–123. doi: 10.1179/096805103125001513. [DOI] [PubMed] [Google Scholar]
  • 94.Garner L.B., Willis M.S., Carlson D.L., et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol. 2003;285:H2500–H2509. doi: 10.1152/ajpheart.00432.2003. [DOI] [PubMed] [Google Scholar]
  • 95.Baumann R., Casaulta C., Simon D., et al. Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB J. 2003;17:2221–2230. doi: 10.1096/fj.03-0110com. [DOI] [PubMed] [Google Scholar]
  • 96.Bozza F.A., Gomes R.N., Japiassu A.M., et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock. 2004;22:309–313. doi: 10.1097/01.shk.0000140305.01641.c8. [DOI] [PubMed] [Google Scholar]
  • 97.Eriandsson Harris H., Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004;34:1503–1512. doi: 10.1002/eji.200424916. [DOI] [PubMed] [Google Scholar]
  • 98.Wang H., Yang H., Tracey K.J. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004;255:320–331. doi: 10.1111/j.1365-2796.2003.01302.x. [DOI] [PubMed] [Google Scholar]
  • 99.Yang H., Ochani M., Li J., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004;101:296–301. doi: 10.1073/pnas.2434651100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Riedermann N.C., Guo R.F., Ward P.A. Novel strategies for the treatment of septic shock. Nat Med. 2003;9:517–524. doi: 10.1038/nm0503-517. [DOI] [PubMed] [Google Scholar]
  • 101.Bouchon A., Facchetti F., Weigand M.A., et al. TREM-1 amplifies inflammation and is crucial mediator of septic shock. Nature. 2001;410:1103–1107. doi: 10.1038/35074114. [DOI] [PubMed] [Google Scholar]
  • 102.Chamaillard M., Hashimoto M., Horie Y., et al. An essential role for NOD-1 in host recognition of peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003;4:702–707. doi: 10.1038/ni945. [DOI] [PubMed] [Google Scholar]
  • 103.Borovikova L.V., Ivanov S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–462. doi: 10.1038/35013070. [DOI] [PubMed] [Google Scholar]
  • 104.Nishio K., Akai Y., Murao Y., et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med. 1997;25:953–957. doi: 10.1097/00003246-199706000-00010. [DOI] [PubMed] [Google Scholar]
  • 105.Landry D.W., Oliver J.A. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588–595. doi: 10.1056/NEJMra002709. [DOI] [PubMed] [Google Scholar]
  • 106.Zimmermann G.A., Mclntyre T.M., Prescott S.M., et al. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002;30(suppl):S294–S301. doi: 10.1097/00003246-200205001-00020. [DOI] [PubMed] [Google Scholar]
  • 107.Shoemaker W.C., Montgomery E.S., Kaplan E., et al. Physiologic patterns in surviving and non-surviving shock patients. Arch Surg. 1973;106:630. doi: 10.1001/archsurg.1973.01350170004003. [DOI] [PubMed] [Google Scholar]
  • 108.Fink M. Cytotoxic hypoxia in sepsis. Acta Anaesthesiol Scand. 1997;110:87–95. doi: 10.1111/j.1399-6576.1997.tb05514.x. [DOI] [PubMed] [Google Scholar]
  • 109.Hayes M.A., Timmins A.C., Yau E.H.S., et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl JMed. 1994;330:1717. doi: 10.1056/NEJM199406163302404. [DOI] [PubMed] [Google Scholar]
  • 110.Rivers E., Nguyen B., Havstadt S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307. [DOI] [PubMed] [Google Scholar]
  • 111.Marshall J.C., Foster D., Vincent J.L., et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the Medic trial. J Infect Dis. 2004;190:527–534. doi: 10.1086/422254. [DOI] [PubMed] [Google Scholar]
  • 112.Sriskandan S., Moyes D., Cohen J. Detection of circulating bacterial superantigen and lymphotoxin alpha in patients with streptococcal toxic-shock syndrome. Lancet. 1986;348:1315. doi: 10.1016/s0140-6736(05)65800-x. [DOI] [PubMed] [Google Scholar]
  • 113.Reinhart K., Wiegand-Lohnert C., Grimminger F., et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 1996;24:733–740. doi: 10.1097/00003246-199605000-00003. [DOI] [PubMed] [Google Scholar]
  • 114.Damas P., Ledoux D., Nys M., et al. Cytokine serum levels during severe sepsis in humans: IL-6 as a marker of severity. Ann Surg. 1992;215:356. doi: 10.1097/00000658-199204000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Fisher C.J., Dhainaut J.F., Opal S.M., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebo-controlled trial. JAMA. 1994;271:1836–1843. [PubMed] [Google Scholar]
  • 116.Karzai W., Oberhoffer M., Meier-Helmann A., et al. Procalcitonin: a new indicator of systemic response to severe infections. Infection. 1997;6:629–634. doi: 10.1007/BF01740811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Gendrel D., Assicot M., Raymond J., et al. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr. 1996;128:570–573. doi: 10.1016/s0022-3476(96)70374-8. [DOI] [PubMed] [Google Scholar]
  • 118.deWerra I., Jacchard C., Corradin S.B., et al. Cytokines, nitrite/ nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentration: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med. 1997;25:607–615. doi: 10.1097/00003246-199704000-00009. [DOI] [PubMed] [Google Scholar]
  • 119.Drakulovic M.B., Torres A., Bauer T.T., et al. Supine body position as a risk factor for nosocominal pneumonia in mechanically ventilated patients: a randomised trial. Lancet. 1999;354:1851–1858. doi: 10.1016/S0140-6736(98)12251-1. [DOI] [PubMed] [Google Scholar]
  • 120.ARDS-Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301. doi: 10.1056/NEJM200005043421801. [DOI] [PubMed] [Google Scholar]
  • 121.Cochrane Injuries Group Albumin Reviewers Human albumin administration in critically ill patients: systematic review of randomized controlled trials. BMJ. 1998;317:235–240. doi: 10.1136/bmj.317.7153.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Wilkes M.M., Navickis R.J. Patient survival after human albumin administration. Ann Intern Med. 2001;135:149–164. doi: 10.7326/0003-4819-135-3-200108070-00007. [DOI] [PubMed] [Google Scholar]
  • 123.Finfers B. R., Boyce N., et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256. doi: 10.1056/NEJMoa040232. [DOI] [PubMed] [Google Scholar]
  • 124.Martin C., Papazian L., Perrin G., et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest. 1993;103:1826. doi: 10.1378/chest.103.6.1826. [DOI] [PubMed] [Google Scholar]
  • 125.Kellum J., Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1752–1758. doi: 10.1097/00003246-200108000-00005. [DOI] [PubMed] [Google Scholar]
  • 126.Marin C., Eon B., Saux P., et al. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med. 1990;18:282. doi: 10.1097/00003246-199003000-00007. [DOI] [PubMed] [Google Scholar]
  • 127.Holmes C.L., Patel B.M., Russell J.A., et al. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989–1002. doi: 10.1378/chest.120.3.989. [DOI] [PubMed] [Google Scholar]
  • 128.Spronk P.F., Ince C., Gardien M.J., et al. Nitroglycerin in septic shock after intravascular fluid resuscitation. Lancet. 2002;360:1395–1396. doi: 10.1016/s0140-6736(02)11393-6. [DOI] [PubMed] [Google Scholar]
  • 129.Wu W., Rathore S.S., Wang Y., et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230–1236. doi: 10.1056/NEJMoa010615. [DOI] [PubMed] [Google Scholar]
  • 130.Corwin H.L., Gettinger A., Rodriguez R.M., et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999;27:2346–2350. doi: 10.1097/00003246-199911000-00004. [DOI] [PubMed] [Google Scholar]
  • 131.Weiskopf R.B., Viely M.K., Feiner J., et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998;279:217–221. doi: 10.1001/jama.279.3.217. [DOI] [PubMed] [Google Scholar]
  • 132.Hebert P.C., Wells G., Blajchman M., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409–417. doi: 10.1056/NEJM199902113400601. [DOI] [PubMed] [Google Scholar]
  • 133.Kudsk K.A., Croce M.A., Fabian T.C., et al. Enteral versus parenteral feeding: effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992;15:503–508. doi: 10.1097/00000658-199205000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Bower R.H., Cerra F.B., Bershadshy B., et al. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter prospective, randomized, clinical trial. Crit Care Med. 1995;23:436–442. doi: 10.1097/00003246-199503000-00006. [DOI] [PubMed] [Google Scholar]
  • 135.Kluger M.J., Kozak W., Conn C., et al. The adaptive value of fever. Infect Dis Clin North Am. 1996;10:1–22. doi: 10.1016/s0891-5520(05)70282-8. [DOI] [PubMed] [Google Scholar]
  • 136.Jiang Q., Cross A.S., Singh I.S., et al. Febrile core temperature is essential for optimal host defense in bacterial peritonitis. Infect Immun. 2000;68:1265–1270. doi: 10.1128/iai.68.3.1265-1270.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Ribeiro S.P., Chu E., Slutsky A.S. Heat stress after injection of LPS in rats decreases mortality. Am J Respir Crit Care Med. 1996;153:A252. [Google Scholar]
  • 138.O’Donnell J., Axelrod R., Fisher C., et al. Use and effectiveness of hypothermia blankets for febrile patients in the intensive care unit. Clin Infect Dis. 1997;24:1208–1211. doi: 10.1086/513660. [DOI] [PubMed] [Google Scholar]
  • 139.Kollef M.H. Optimizing antibiotic therapy in the intensive care unit setting. Critical Care. 2001;5:189–195. doi: 10.1186/cc1022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140.Ibrahim E.M., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of blood stream infection on patient outcomes in the ICU setting. Chest. 2000;118:146–155. doi: 10.1378/chest.118.1.146. [DOI] [PubMed] [Google Scholar]
  • 141.Rao A.K., Chouhan V., Chen X., et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes. 2002;48:1156–1161. doi: 10.2337/diabetes.48.5.1156. [DOI] [PubMed] [Google Scholar]
  • 142.van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1349–1346. doi: 10.1056/NEJMoa011300. [DOI] [PubMed] [Google Scholar]
  • 143.Annane D., Sebille V., Charpentier C., et al. Effects of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–871. doi: 10.1001/jama.288.7.862. [DOI] [PubMed] [Google Scholar]
  • 144.Schroeder S., Wichers M., Klingmuller D., et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med. 2001;29:310–316. doi: 10.1097/00003246-200102000-00017. [DOI] [PubMed] [Google Scholar]
  • 145.Keh D., Boehnke T., Weber-Cartens S., et al. Immunologic and hemodynamic effects of “low dose” hydrocortisone in septic shock. A double-blind, randomized, placebo-controlled crossover study. Am J Respir Crit Care Med. 2003;167:512–520. doi: 10.1164/rccm.200205-446OC. [DOI] [PubMed] [Google Scholar]

Articles from Surgery are provided here courtesy of Nature Publishing Group

RESOURCES